Insmed Presents at Goldman Sachs; Reiterates Existing Guidance

What happened

Insmed presented at the Goldman Sachs 47th Annual Global Healthcare Conference, with management reiterating the company's key investment themes: BRINSUPRI's strong launch trajectory, the upcoming ARIKAYCE sNDA filing, and the path to cash-flow positivity in 2027. The presentation did not introduce any new financial guidance or material updates beyond what was disclosed in the Q1 2026 earnings call on May 7, 2026. The market reacted mildly, with the stock trading around $94, reflecting the absence of a positive catalyst. The focus remains on execution: BRINSUPRI must show sequential growth from Q1's $207.9M, and SG&A growth needs to decelerate to prove operating leverage. The ARIKAYCE ENCORE sNDA timeline and potential Japan approval for BRINSUPRI remain the next tangible catalysts.

Implication

The conference reaffirmation confirms the existing thesis but adds no new upside. Investors should monitor Q2 2026 results for signs of operating leverage and BRINSUPRI demand quality. If SG&A growth slows and BRINSUPRI shows sequential growth, the base case of $110 remains achievable. Failure to meet those metrics would strengthen the bear case of $60.

Thesis delta

No change. The presentation reinforced the current narrative without altering expectations. The key watchpoints remain BRINSUPRI's organic demand progression and cost control.